Pathway Financial Advisers LLC Lowers Stock Position in Amgen Inc. $AMGN

Pathway Financial Advisers LLC cut its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 35.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,887 shares of the medical research company’s stock after selling 5,382 shares during the quarter. Pathway Financial Advisers LLC’s holdings in Amgen were worth $3,479,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of AMGN. Brighton Jones LLC raised its position in shares of Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after buying an additional 5,226 shares in the last quarter. Sivia Capital Partners LLC grew its position in Amgen by 10.6% in the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after acquiring an additional 114 shares in the last quarter. Schnieders Capital Management LLC. increased its stake in Amgen by 29.3% in the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock valued at $7,220,000 after acquiring an additional 5,853 shares during the last quarter. Main Street Financial Solutions LLC raised its position in Amgen by 11.3% during the second quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company’s stock valued at $1,141,000 after purchasing an additional 416 shares in the last quarter. Finally, Ieq Capital LLC raised its position in Amgen by 5.1% during the second quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company’s stock valued at $15,120,000 after purchasing an additional 2,611 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Guggenheim cut their price objective on Amgen from $351.00 to $340.00 and set a “neutral” rating for the company in a report on Monday, May 4th. Mizuho raised their price objective on Amgen from $295.00 to $303.00 and gave the company a “neutral” rating in a report on Tuesday, June 16th. Wall Street Zen lowered Amgen from a “buy” rating to a “hold” rating in a research note on Saturday. Argus reduced their price target on shares of Amgen from $400.00 to $375.00 and set a “buy” rating on the stock in a research report on Wednesday, May 20th. Finally, Daiwa Securities Group decreased their price target on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 13th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Amgen presently has an average rating of “Hold” and a consensus target price of $354.42.

Amgen Trading Up 0.6%

Shares of AMGN stock opened at $360.55 on Tuesday. The stock has a market capitalization of $194.59 billion, a PE ratio of 25.09, a P/E/G ratio of 3.60 and a beta of 0.42. Amgen Inc. has a 1-year low of $269.77 and a 1-year high of $391.29. The business has a 50-day moving average of $340.92 and a 200 day moving average of $346.71. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. During the same period in the previous year, the firm earned $4.90 EPS. The business’s quarterly revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 22.38 earnings per share for the current year.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.85% of the company’s stock.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.